- Home
- OVID vs XFOR Comparison
OVID vs XFOR Comparison
Compare OVID & XFOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OVID
- XFOR
- Stock Information
- Founded
- OVID 2014
- XFOR 2014
- Country
- OVID United States
- XFOR United States
- Employees
- OVID N/A
- XFOR N/A
- Industry
- OVID Biotechnology: Pharmaceutical Preparations
- XFOR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- OVID Health Care
- XFOR Health Care
- Exchange
- OVID Nasdaq
- XFOR Nasdaq
- Market Cap
- OVID 88.9M
- XFOR 84.3M
- IPO Year
- OVID 2017
- XFOR N/A
- Fundamental
- Price
- OVID $1.27
- XFOR $3.08
- Analyst Decision
- OVID Strong Buy
- XFOR Strong Buy
- Analyst Count
- OVID 4
- XFOR 3
- Target Price
- OVID $3.13
- XFOR $34.17
- AVG Volume (30 Days)
- OVID 1.5M
- XFOR 1.6M
- Earning Date
- OVID 11-11-2025
- XFOR 11-12-2025
- Dividend Yield
- OVID N/A
- XFOR N/A
- EPS Growth
- OVID N/A
- XFOR N/A
- EPS
- OVID N/A
- XFOR N/A
- Revenue
- OVID $6,651,000.00
- XFOR $32,774,000.00
- Revenue This Year
- OVID $708.13
- XFOR $1,313.84
- Revenue Next Year
- OVID N/A
- XFOR N/A
- P/E Ratio
- OVID N/A
- XFOR N/A
- Revenue Growth
- OVID 1070.95
- XFOR 5721.31
- 52 Week Low
- OVID $0.24
- XFOR $1.35
- 52 Week High
- OVID $1.47
- XFOR $26.83
- Technical
- Relative Strength Index (RSI)
- OVID 55.01
- XFOR 49.23
- Support Level
- OVID N/A
- XFOR $2.95
- Resistance Level
- OVID $1.35
- XFOR $3.79
- Average True Range (ATR)
- OVID 0.10
- XFOR 0.38
- MACD
- OVID -0.07
- XFOR -0.12
- Stochastic Oscillator
- OVID 93.78
- XFOR 6.84
About OVID Ovid Therapeutics Inc.
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.
About XFOR X4 Pharmaceuticals Inc.
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.